Imugene Appoints Dr. John Byon as Chief Medical Officer to Advance Cancer Immunotherapy

Imugene Limited ( (AU:IMU) ) has shared an update.

Imugene Limited has appointed Dr. John Byon as its new Chief Medical Officer. Dr. Byon, who has a strong background in oncology drug development, has been pivotal in advancing Imugene’s strategy to combine its allogeneic CAR-T therapy, azer-cel, with interleukin-2 (IL-2), significantly improving treatment outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma. His appointment is expected to further strengthen Imugene’s clinical pipeline and its efforts towards commercializing innovative cancer treatments.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.

More about Imugene Limited

Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer immunotherapies. The company specializes in CAR-T cell therapy and is actively involved in enhancing therapeutic efficacy and durability for patients with hematologic malignancies.

Average Trading Volume: 23,864,849

Technical Sentiment Signal: Sell

Current Market Cap: A$126.9M

For an in-depth examination of IMU stock, go to TipRanks’ Stock Analysis page.